Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 11, 2007

GeneGo and the Cystic Fibrosis Foundation Are Building Software to Aid Research

  • GeneGo and the Cystic Fibrosis Foundation are partnering to develop software for the integration and analysis of cystic fibrosis data. The product, which will be called MetaMiner (CF), is intended to be used by medicinal chemists and biologists active in preclinical areas of high-content and high-throughput screening, bioassays, and hit-to-lead research.

    MetaMiner (CF) is expected to be available by February of 2008 to cystic fibrosis academic researchers and drug development collaborators through access licenses. It will include cystic fibrosis-specific OMICs and small experiments content annotated by GeneGo, disease maps, and networks.

    GeneGo products such as MetaCore, MetaDrug, MetaLink, and MapEditor will be incorporated in the product. “This collaboration is the first in the series of disease-centered MetaMiner projects that integrate our existing data analysis tools, OMICs data warehousing, and disease-specific knowledge base,” points out Julie Bryant, GeneGo's vp of business development.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »